Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495793 · ClinicalTrials.gov registry record · Phase 2
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
A Phase 2 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01495793 is a Phase 2 study that has completed, run by UCB Biosciences. The registered enrollment target is 42 participants.
The verdict
NCT01495793, a Phase 2 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system. The study was conducted in adolescent subjects (13 to \<18 years of age) with idiopathic Restless Legs Syndrome (RLS).
Interventions
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495793
The ClinicalTrials.gov registry entry for NCT01495793 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rotigotine is the first listed.
NCT01495793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01495793 about?
NCT01495793 is a clinical study titled "Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome". This was a multicenter, open-label, dose-escalation, Phase 2A study with multiple administrations of the rotigotine transdermal system. The study was conducted in adolescent subjects (13 to \<18 years of age) with idiopathic Restless Legs Syndrome (RLS).
What is the current status of trial NCT01495793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2011-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01495793?
The interventions under investigation include: Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01495793?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.